Literature DB >> 19144659

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

Hermann Brenner1, Adam Gondos, Dianne Pulte.   

Abstract

New therapeutic options have led to substantial increases in survival expectations of younger patients with multiple myeloma in recent years. In the past, the impact of these innovations on long-term survival has been disclosed only with substantial delay. We aimed to derive up-to-date estimates of long-term survival expectations of concurrently diagnosed multiple myeloma patients. Using data from the 1973-2005 database of the Surveillance, Epidemiology, and End Results (SEER) Program, we employed a novel model-based projection method to project 5-and 10-year relative survival expectations of multiple myeloma patients in the United States diagnosed in 2006-2010. Preliminary empirical evaluation of the method using historical data indicated good performance. Projected 5-year relative survival for patients diagnosed in 2006-2010 below 45 years of age is 68.0%, which exceeds the most up-to-date estimates obtained from traditional cohort and period analysis by 15.5 and 7.0 percent units respectively. Ten-year relative survival projection for patients in this age group is 55.3%, exceeding the most up-to-date estimates from traditional cohort and period analysis by 19.7 and 7.4 percent units respectively. By contrast, survival projections remain much lower and hardly exceed estimates from traditional survival analysis for older patients. Patients diagnosed with multiple myeloma in 2006-2010, especially those diagnosed at younger ages, are expected to have much higher long-term survival perspectives than suggested by previously available survival statistics.

Entities:  

Mesh:

Year:  2009        PMID: 19144659      PMCID: PMC2635407          DOI: 10.3324/haematol.13782

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  18 in total

1.  The relative survival rate: a statistical methodology.

Authors:  F EDERER; L M AXTELL; S J CUTLER
Journal:  Natl Cancer Inst Monogr       Date:  1961-09

2.  Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael Schuster; David Irwin; Edward Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus San Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; Melissa Alsina; S Vincent Rajkumar; Martha Lacy; Andrzej Jakubowiak; William Dalton; Anthony Boral; Dixie-Lee Esseltine; David Schenkein; Kenneth C Anderson
Journal:  Blood       Date:  2007-08-09       Impact factor: 22.113

3.  Estimates of cancer incidence and mortality in Europe in 1995.

Authors:  F Bray; R Sankila; J Ferlay; D M Parkin
Journal:  Eur J Cancer       Date:  2002-01       Impact factor: 9.162

4.  The relative survival rate.

Authors:  D E Henson; L A Ries
Journal:  Cancer       Date:  1995-11-15       Impact factor: 6.860

5.  Up-to-date estimates of cancer patient survival even with common latency in cancer registration.

Authors:  Hermann Brenner; Timo Hakulinen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-09       Impact factor: 4.254

6.  Antitumor activity of thalidomide in refractory multiple myeloma.

Authors:  S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal:  N Engl J Med       Date:  1999-11-18       Impact factor: 91.245

7.  Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Authors:  Donna M Weber; Christine Chen; Ruben Niesvizky; Michael Wang; Andrew Belch; Edward A Stadtmauer; David Siegel; Ivan Borrello; S Vincent Rajkumar; Asher Alban Chanan-Khan; Sagar Lonial; Zhinuan Yu; John Patin; Marta Olesnyckyj; Jerome B Zeldis; Robert D Knight
Journal:  N Engl J Med       Date:  2007-11-22       Impact factor: 91.245

8.  Lymphoma survival patterns by WHO subtype in the United States, 1973-2003.

Authors:  Xuesong Han; Briseis Kilfoy; Tongzhang Zheng; Theodore R Holford; Cairong Zhu; Yong Zhu; Yawei Zhang
Journal:  Cancer Causes Control       Date:  2008-03-26       Impact factor: 2.506

Review 9.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

Review 10.  Thalidomide for treatment of multiple myeloma: 10 years later.

Authors:  Antonio Palumbo; Thierry Facon; Pieter Sonneveld; Joan Bladè; Massimo Offidani; Francesca Gay; Philippe Moreau; Anders Waage; Andrew Spencer; Heinz Ludwig; Mario Boccadoro; Jean-Luc Harousseau
Journal:  Blood       Date:  2008-02-01       Impact factor: 22.113

View more
  38 in total

1.  Impact of age, race and decade of treatment on overall survival in a critical population analysis of 40,000 multiple myeloma patients.

Authors:  Hakan Kaya; Benjamin Peressini; Irfan Jawed; Danko Martincic; Ameer L Elaimy; Wayne T Lamoreaux; Robert K Fairbanks; Kevin A Weeks; Christopher M Lee
Journal:  Int J Hematol       Date:  2011-12-09       Impact factor: 2.490

Review 2.  Changing paradigms in the treatment of multiple myeloma.

Authors:  Joan Bladé; Laura Rosiñol
Journal:  Haematologica       Date:  2009-02       Impact factor: 9.941

3.  Statin use and risk of multiple myeloma: An analysis from the cancer research network.

Authors:  Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson
Journal:  Int J Cancer       Date:  2017-05-15       Impact factor: 7.396

4.  Advances in current treatment for patients with newly diagnosed multiple myeloma.

Authors:  S Lonial
Journal:  Leuk Suppl       Date:  2013-05-08

Review 5.  Optimal management of cancer treatment-induced bone loss: considerations for elderly patients.

Authors:  Karen Tipples; Anne Robinson
Journal:  Drugs Aging       Date:  2011-11-01       Impact factor: 3.923

6.  Regular aspirin use and risk of multiple myeloma: a prospective analysis in the health professionals follow-up study and nurses' health study.

Authors:  Brenda M Birmann; Edward L Giovannucci; Bernard A Rosner; Graham A Colditz
Journal:  Cancer Prev Res (Phila)       Date:  2013-11-26

Review 7.  Bortezomib: a review of its use in patients with multiple myeloma.

Authors:  Monique P Curran; Kate McKeage
Journal:  Drugs       Date:  2009       Impact factor: 9.546

Review 8.  The Tao of myeloma.

Authors:  Lawrence H Boise; Jonathan L Kaufman; Nizar J Bahlis; Sagar Lonial; Kelvin P Lee
Journal:  Blood       Date:  2014-09-18       Impact factor: 22.113

9.  Randomized clinical trial of zoledronic acid in multiple myeloma patients undergoing high-dose chemotherapy and stem-cell transplantation.

Authors:  A Avilés; N Neri; J Huerta-Guzmán; M J Nambo
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

10.  A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma.

Authors:  Paul G Richardson; Wanling Xie; Sundar Jagannath; Andrzej Jakubowiak; Sagar Lonial; Noopur S Raje; Melissa Alsina; Irene M Ghobrial; Robert L Schlossman; Nikhil C Munshi; Amitabha Mazumder; David H Vesole; Jonathan L Kaufman; Kathleen Colson; Mary McKenney; Laura E Lunde; John Feather; Michelle E Maglio; Diane Warren; Dixil Francis; Teru Hideshima; Robert Knight; Dixie-Lee Esseltine; Constantine S Mitsiades; Edie Weller; Kenneth C Anderson
Journal:  Blood       Date:  2014-01-15       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.